<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02426879</url>
  </required_header>
  <id_info>
    <org_study_id>NL48231.041.14</org_study_id>
    <nct_id>NCT02426879</nct_id>
  </id_info>
  <brief_title>Esophagectomy for Patients With Esophageal Cancer and Cervical Lymph Node Metastases</brief_title>
  <acronym>Node</acronym>
  <official_title>Esophagectomy for Patients With Esophageal Cancer and Cervical Lymph Node Metastases Node Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no world-wide consensus on the oncological benefit versus increased morbidity&#xD;
      associated with three field lymphadenectomy in patients with esophageal cancer and cervical&#xD;
      lymph node metastases. In Asian countries, esophagectomy is commonly combined with a three&#xD;
      field lymphadenectomy, including resection of cervical, thoracic and abdominal lymph nodes.&#xD;
      However, in Western countries patients with cervical lymph node metastases are generally&#xD;
      precluded from curative treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To assess the safety and feasibility of curative esophagectomy combined with three&#xD;
      field lymphadenectomy after chemo-radiation in Western patients with resectable thoracic&#xD;
      esophageal carcinoma and cervical lymph node metastases. Secondary objective is to determine&#xD;
      the effect on survival and recurrence.&#xD;
&#xD;
      Study design: Mono centre prospective phase II single-arm feasibility study. Study&#xD;
      population: Western patients diagnosed with resectable (cT1-4a, N1-3) intra thoracic&#xD;
      esophageal carcinoma with histological or cytological proven cervical lymph node metastases&#xD;
      in level III and/ or IV.&#xD;
&#xD;
      Intervention: Transthoracic esophageal resection combined with three field lymphadenectomy&#xD;
      after neoadjuvant chemo-radiation.&#xD;
&#xD;
      Main study parameters/ endpoints: Primary outcome is the percentage of overall surgical&#xD;
      complications grade 3b and higher as stated by the Modified Clavien-Dindo classification.&#xD;
      Secondary outcomes are mortality, operation related events and postoperative recovery,&#xD;
      including quality of life, disease free survival, overall survival and if applicable the&#xD;
      location of recurrent disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 11, 2015</start_date>
  <completion_date type="Actual">January 25, 2021</completion_date>
  <primary_completion_date type="Actual">January 25, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measured by the percentage of overall postoperative complications grade 3b and higher as stated by the modified Clavien-Dindo classification (MCDC)</measure>
    <time_frame>5 years</time_frame>
    <description>Safety is measured by the percentage of overall postoperative complications grade 3b and higher as stated by the modified Clavien-Dindo classification (MCDC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>5 years</time_frame>
    <description>in-hospital mortality and 30- and 60 day mortality (absolute numbers/ percentages)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>5 years</time_frame>
    <description>5 year overall- and disease free survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life measured by questionnaires (EORTC-QLQ_C30 and EORTC-QLQ_Oes18)</measure>
    <time_frame>10 years</time_frame>
    <description>QoL is measured by questionnaires (EORTC-QLQ_C30 and EORTC-QLQ_Oes18)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operation related events 1</measure>
    <time_frame>5 years</time_frame>
    <description>duration of surgery (minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operation related events 2</measure>
    <time_frame>5 years</time_frame>
    <description>reason for prolongation of surgery if applicable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operation related events 3</measure>
    <time_frame>5 years</time_frame>
    <description>unexpected events/ complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operation related events 4</measure>
    <time_frame>5 years</time_frame>
    <description>bloodloss (ml) reason for conversion if applicable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operation related events 5</measure>
    <time_frame>5 years</time_frame>
    <description>reason for conversion if applicable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative recovery</measure>
    <time_frame>5 years</time_frame>
    <description>duration of intubation (days), length of ICU/ MCU stay(days), length of hospital stay (days),</description>
  </secondary_outcome>
  <other_outcome>
    <measure>pathology results 1</measure>
    <time_frame>5 years</time_frame>
    <description>pTNM stage</description>
  </other_outcome>
  <other_outcome>
    <measure>pathology results 2</measure>
    <time_frame>5 years</time_frame>
    <description>site of tumour</description>
  </other_outcome>
  <other_outcome>
    <measure>pathology results 3</measure>
    <time_frame>5 years</time_frame>
    <description>length of tumour</description>
  </other_outcome>
  <other_outcome>
    <measure>pathology results 4</measure>
    <time_frame>5 years</time_frame>
    <description>type of tumour</description>
  </other_outcome>
  <other_outcome>
    <measure>pathology results 5</measure>
    <time_frame>5 years</time_frame>
    <description>gradation of tumour</description>
  </other_outcome>
  <other_outcome>
    <measure>pathology results 6</measure>
    <time_frame>5 years</time_frame>
    <description>margins of resection (R0, R1, R2)</description>
  </other_outcome>
  <other_outcome>
    <measure>pathology results 7</measure>
    <time_frame>5 years</time_frame>
    <description>mandard score</description>
  </other_outcome>
  <other_outcome>
    <measure>pathology results 8</measure>
    <time_frame>5 years</time_frame>
    <description>lymphnode status</description>
  </other_outcome>
  <other_outcome>
    <measure>pathology results 9</measure>
    <time_frame>5 years</time_frame>
    <description>vaso-invasion</description>
  </other_outcome>
  <other_outcome>
    <measure>pathology results 10</measure>
    <time_frame>5 years</time_frame>
    <description>perineural growth</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Cancer</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <condition>Adenocarcinoma</condition>
  <condition>Malignancy</condition>
  <arm_group>
    <arm_group_label>surgery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>esophagectomy with three-field lymphnode dissection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>esophagectomy with three-field lymphnode dissection</intervention_name>
    <description>robot assisted thoraco-laparoscopic esophagectomy with three-field lymphnode dissection</description>
    <arm_group_label>surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven squamous cell carcinoma or adenocarcinoma of the esophagus.&#xD;
&#xD;
          -  Surgical resectable carcinoma (T1-4a, N1-3) (table 1)&#xD;
&#xD;
          -  Histologically/ cytologically proven resectable cervical lymph node metastases level&#xD;
             III and/ or IV&#xD;
&#xD;
          -  Age â‰¥ 18&#xD;
&#xD;
          -  European Clinical Oncology Group (ECOG) performance status 0,1 or 2&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Distant metastases&#xD;
&#xD;
          -  Esophageal carcinoma &lt; 3 cm beneath UES&#xD;
&#xD;
          -  Carcinoma of the gastro-esophageal junction (GEJ) with major tumor in the gastric&#xD;
             cardia (Siewert III)&#xD;
&#xD;
          -  Former radiotherapy or chemotherapy for esophageal carcinoma&#xD;
&#xD;
          -  Former radiotherapy precluding radiotherapy according the CROSS protocol&#xD;
&#xD;
          -  Inadequate pulmonary function disabling transthoracic resection&#xD;
&#xD;
          -  &gt;10% loss of weight in the last six months&#xD;
&#xD;
          -  Previous neck dissection&#xD;
&#xD;
          -  New York heart association class III/IV and no history of active angina. Patients with&#xD;
             a history of significant ventricular arrhythmia requiring medication or congestive&#xD;
             heart failure. History of 2nd or 3rd degree heart blocks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard V Hillegersberg, Prof Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>April 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2015</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Richard van Hillegersberg</investigator_full_name>
    <investigator_title>prof Dr</investigator_title>
  </responsible_party>
  <keyword>three-field lymphadenectomy</keyword>
  <keyword>cervical metastases</keyword>
  <keyword>esophagectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Lymphatic Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

